Tarsheen Sethi, MD, MSc
Assistant Professor of Medicine (Hematology)Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director, Yale Affiliated Hospital Program for Hematology Section, Internal Medicine
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director, Yale Affiliated Hospital Program for Hematology Section, Internal Medicine
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director, Yale Affiliated Hospital Program for Hematology Section, Internal Medicine
Contact Info
About
Titles
Assistant Professor of Medicine (Hematology)
Director, Yale Affiliated Hospital Program for Hematology Section, Internal Medicine
Biography
Tarsheen Sethi, MD, MSCI, is an Assistant Professor of Medicine (Hematology) and cares primarily for patients with Hodgkin and Non-Hodgkin lymphomas. Under the mentorship of Dr. Francine Foss, Dr. Sethi sees patients of all lymphoma subtypes, including T-cell lymphomas and Chronic Leukocytic Leukemia. Dr. Sethi joined Smilow from Vanderbilt University Medical School where she was an Instructor of Medicine in their Division of Hematology-Oncology.
Dr. Sethi received her Medical Degree from the Maulana Azad Medical College in New Delhi, India, and her Master of Science in Clinical Investigation at Vanderbilt University, where she also completed her fellowship in Hematology-Oncology. As a post-doctoral research fellow at the Stanford Molecular Imaging Program, Dr. Sethi received the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation Award in Translational Medicine and Therapeutics. With this research training background, she is involved in clinical and translational research projects aimed at improving care and outcomes of Hodgkin and Non-Hodgkin lymphoma patients. Dr. Sethi’s research includes clinical trials targeting lymphomas involving novel drugs and combinations. She is also interested in studying the applications of tumor immunology and immunotherapy to hematologic malignancies, focusing on lymphoma.
Appointments
Hematology
Assistant ProfessorPrimary
Other Departments & Organizations
- Hematology
- Internal Medicine
- Leukemia & Lymphoma Program
- Yale Cancer Center
- Yale Medicine
Education & Training
- Clinical Fellow and Advanced Fellow
- Vanderbilt University Medical Center (2018)
- MSc
- Vanderbilt University, Clinical Investigation (2018)
- Intern and Resident Physician
- University of Louisville (2013)
- Chief Resident
- Maulana Azad Medical College (2009)
- MD
- Maulana Azad Medical College (2008)
- Resident Physician
- Maulana Azad Medical College (2008)
- MBBS
- Maulana Azad Medical College (2005)
Research
Overview
Her research is aimed at improving care and outcomes of Hodgkin and Non-Hodgkin lymphoma patients. She is also interested in studying the applications of tumor immunology and immunotherapy to hematologic malignancies focusing on lymphoma.
Medical Research Interests
ORCID
0000-0002-1346-2103
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Shalin Kothari, MD
Francine Foss, MD
Francesca Montanari, MD
Scott Huntington, MD, MPH, MSc
Amer Zeidan, MBBS
Iris Isufi, MD
Lymphoma
Publications
2024
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation
Epperla N, Huang Y, Cashen A, Vaughn J, Hanel W, Badar T, Barta S, Caimi P, Sethi T, Reddy N, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Svoboda J, Lansigan F, Glenn M, Cohen J, Sorge C, Christian B, Herrera A, Hamadani M, Costa L, Xavier A. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood Advances 2024, 8: 5458-5466. PMID: 39213424, PMCID: PMC11532746, DOI: 10.1182/bloodadvances.2024013743.Peer-Reviewed Original ResearchAltmetricConceptsPrimary treatment failureAuto-HCTStable diseaseHodgkin lymphomaPartial responseCumulative incidence of non-relapse mortalityIncidence of non-relapse mortalityAssociated with inferior PFSEfficacy of auto-HCTAssociated with inferior OSAutologous hematopoietic cell transplantationEvaluation of prognostic factorsClassical Hodgkin lymphomaNon-relapse mortalityMulticenter retrospective cohortHigh-risk diseaseHematopoietic cell transplantationLong-term efficacyPatterns of failureUS medical centersProgression of diseaseInferior PFSMedian PFSInferior OSComplete responseReal World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma
Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.Peer-Reviewed Original ResearchAltmetricConceptsT-cell lymphomaHeterogeneous group of lymphoid malignanciesGroup of lymphoid malignanciesPeripheral T-cell lymphomaAggressive T-cell lymphomaCutaneous T-cell lymphomaT cellsResponse rateR/R settingComplete responseLymphoid malignanciesPoor outcomeAnaplastic large cell lymphomaFrontline treatment regimensLarge cell lymphomaCombination of prednisoneHeterogeneous groupCell lymphomaChemotherapy optionsCaucasian patientsFirst-linePositive patientsTreatment regimensGrade 3LymphomaCharacterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023.
Warner J, Bakow B, Brown A, Choe J, Fan E, Ganta T, Glover M, Hadfield M, Hilton C, Khaki A, Kothari S, Lythgoe M, Nagpal S, Nguyen R, Noyd D, Riaz I, Rooney M, Sethi T, Singhi E, Rubinstein S. Characterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023. Journal Of Clinical Oncology 2024, 42: 11079-11079. DOI: 10.1200/jco.2024.42.16_suppl.11079.Peer-Reviewed Original ResearchConceptsPhase 3 randomized clinical trialPhase 3 RCTsPrimary endpointClinical trialsEligible publicationsProlific authorsSystemic anticancer therapySuccess rateMann-Whitney U testStandard of carePositive publication biasTrial sample sizePositive resultsYear of publicationPublication biasTherapeutic advancesPrimary outcomeAuthorship patternAnticancer therapyExperimental armAuthor's outputMann-WhitneyU testInterquartile rangeAuthor informationEvaluation of the study of control arms in randomized clinical trials of cancer.
Jain S, Zauderer M, Sethi T, Schoen M, Rubinstein S, Nguyen R, Nagpal S, Mohan S, Madireddy S, Lythgoe M, Liang W, Kulkarni A, Kothari S, Hilal T, Hadfield M, Goyal G, Ganta T, Dholaria B, Brown A, Warner J. Evaluation of the study of control arms in randomized clinical trials of cancer. Journal Of Clinical Oncology 2024, 42: 11023-11023. DOI: 10.1200/jco.2024.42.16_suppl.11023.Peer-Reviewed Original ResearchConceptsRandomized clinical trialsSystemic anti-cancer therapyCancer randomized clinical trialsControl armSuccess rateClinical trials of cancerFisher's exact testAnti-cancer therapyTrial success ratesStudy publication yearExact testPatient convenienceRegimensClinical trialsHighest success rateExperimental armCancer typesCancerContext of treatmentPublication yearTrialsDoseNon-cancerEfficacyDyads
2023
Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis
Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica 2023, 108: 2218-2223. PMID: 36655436, PMCID: PMC10388284, DOI: 10.3324/haematol.2022.282252.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsSethi TK, Kothari S , Mulvey E, Foss F, Leonard J, Greer J. Non-Hodgkin Lymphoma in Adults
Means, Robert T.(2023). Wintrobe's Clinical Hematology (15th Edition). Lippincott Williams & Wilkins (LWW).ChaptersPrimary Cutaneous Lymphomas
Perez & Brady's Principles and Practice of Radiation Oncology (8th edition). In Press.Chapters
2022
A multicenter, real‐world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus
Dittus C, Grover N, Sethi T, Cohen JB, Voloschin A, Rabadey J, Tan X, Beaven A, Park SI. A multicenter, real‐world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus. EJHaem 2022, 3: 734-738. PMID: 36051081, PMCID: PMC9421958, DOI: 10.1002/jha2.474.Peer-Reviewed Original ResearchCitationsAltmetricHuman herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics
Gisriel SD, Yuan J, Braunberger RC, Maracaja DLV, Chen X, Wu X, McCracken J, Chen M, Xie Y, Brown LE, Li P, Zhou Y, Sethi T, McHenry A, Hauser RG, Paulson N, Tang H, Hsi ED, Wang E, Zhang QY, Young KH, Xu ML, Pan Z. Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. Modern Pathology 2022, 35: 1411-1422. PMID: 35562413, PMCID: PMC9926946, DOI: 10.1038/s41379-022-01091-x.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsLarge B-cell lymphomaDistinct clinicopathologic characteristicsMedian overall survivalB-cell lymphomaOverall survivalClinicopathologic characteristicsPrimary effusion lymphomaHHV8 infectionLymphomatous effusionsNon-germinal center B-cell subtypeLonger median overall survivalUnique clinicopathologic characteristicsFavorable prognostic factorEpstein-Barr virusSeparate diagnostic criteriaHuman herpesvirus 8B-cell subtypeMulti-institutional studyNon-Japanese casesDiagnostic uniformityImmunocompetent patientsPericardial effusionPericardial involvementSelect patientsChemotherapy administrationSafety considerations with the current treatments for peripheral T-cell lymphoma
Sethi T, Montanari F, Foss F. Safety considerations with the current treatments for peripheral T-cell lymphoma. Expert Opinion On Drug Safety 2022, 21: 653-660. PMID: 35129014, DOI: 10.1080/14740338.2022.2036120.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricMeSH Keywords and ConceptsConceptsPeripheral T-cell lymphomaT-cell lymphomaCombination chemotherapyTreatment regimensAnthracycline-based combination chemotherapyNK-T cell lymphomaB-cell non-Hodgkin lymphomaSingle-agent chemotherapyAvailable treatment regimensNon-Hodgkin lymphomaT cell subtypesSelection of agentsRelapsed settingAgent chemotherapyNatural killerFrontline treatmentPoor prognosisDisease groupUnique immunobiologyCurrent treatmentCell lymphomaCell disordersSide effectsLymphomaCertain complications
Clinical Trials
Current Trials
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients with Lymphomas That Have Resisted Treatment
HIC ID2000034565RolePrincipal InvestigatorPrimary Completion Date03/01/2024Recruiting ParticipantsPhase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
HIC ID2000029793RolePrincipal InvestigatorPrimary Completion Date04/30/2028Recruiting ParticipantsPhase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma
HIC ID2000032539RoleSub InvestigatorPrimary Completion Date05/19/2029Recruiting ParticipantsA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
HIC ID2000030190RoleSub InvestigatorPrimary Completion Date06/02/2026Recruiting Participants
Academic Achievements & Community Involvement
activity Yale Cancer Center Protocol Review Committee (PRC)
CommitteesMemberDetails2022 - Presentactivity Yale Affiliated Hospitals Program (YAHP)-Hematology
CommitteesDirectorDetails2022 - Presentactivity New England Hematologic Malignancies Symposium
Meeting Planning and ParticipationAbstract ReviewerDetails07/01/2023 - Presentactivity British Journal of Hematology
Journal ServiceReviewerDetails10/01/2015 - Presentactivity Bone Marrow Transplantation
Journal ServiceReviewerDetails10/01/2015 - Present
Clinical Care
Overview
Tarsheen Sethi, MD, MSCI (master of science in clinical investigation), is a hematologist who specializes in treating patients with Hodgkin and non-Hodgkin lymphoma—cancers that begin in white blood cells called lymphocytes, which are an important part of the immune system.
An active researcher, Dr. Sethi focuses on treatments using new drugs and multi-drug combinations on all types of lymphomas. Some of her research addresses treatment of a rare category of lymphomas, hastening patient referrals, improving quality of life, and coordinating the use of different drugs.
As the understanding of cancer has become more specific and treatments more complex and targeted, Dr. Sethi has worked to help build a database of information on chemotherapy treatments that is shared freely throughout the world.
Clinical Specialties
Fact Sheets
Acute Myeloid Leukemia (AML)
Learn More on Yale MedicineDiagnosing Leukemia
Learn More on Yale MedicineCytogenic Studies for Leukemia Diagnosis
Learn More on Yale MedicineLeukemia in Children
Learn More on Yale Medicine
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews & Links
News
Related Links
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.